Medicure Company Description

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.

The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction.

It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia.

It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.